Summary

Prostate Health Market – Scope of Report
TMR’s report on the global prostate health market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global prostate health market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global prostate health market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the prostate health market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global prostate health market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global prostate health market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global prostate health market.

The report delves into the competitive landscape of the global prostate health market. Key players operating in the global prostate health market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global prostate health market profiled in this report.

Key Questions Answered in Global prostate health Market Report
• What is the sales/revenue generated by prostate health across all regions during the forecast period?
• What are the opportunities in the global prostate health market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Prostate Health Market – Research Objectives and Research Approach
The comprehensive report on the global prostate health market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global prostate health market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global prostate health market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Prostate Health Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Prostate Health Market Analysis and Forecast, 2020-2034
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Regulatory Scenario by region/globally
5.2. Key Industry Events (Product Launches, Collaborations and Partnerships, Acquisitions, Approvals etc.)
5.3. Pipeline Analysis
5.4. Reimbursement Scenario by Key Countries
5.5. Disease Diagnosis of Prostate Diseases (Prostatitis, Benign Prostate Hyperplasia, Prostate Cancer, etc.)
5.6. Brand Analysis
5.7. Pricing Analysis
5.8. Covid-19 Pandemic Impact on Industry
6. Global Prostate Health Market Analysis and Forecast, by Disease Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Disease Type, 2020-2034
6.3.1. Prostatitis
6.3.2. Benign Prostatic Hyperplasia (BPH)
6.3.3. Prostate Cancer
6.3.3.1. Adenocarcinoma
6.3.3.2. Transitional Cell Carcinoma
6.3.3.3. Squamous Cell Carcinoma
6.3.3.4. Small Cell Prostate Cancer
6.4. Market Attractiveness Analysis, by Disease Type
7. Global Prostate Health Market Analysis and Forecast, by Treatment
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Treatment, 2020-2034
7.3.1. Chemotherapy
7.3.2. Hormone Therapy
7.3.3. Immunotherapy
7.4. Market Attractiveness Analysis, by Treatment
8. Global Prostate Health Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Route of Administration, 2020-2034
8.3.1. Oral
8.3.2. Parenteral
8.4. Market Attractiveness Analysis, by Route of Administration
9. Global Prostate Health Market Analysis and Forecast, by Distribution Channel
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Distribution Channel, 2020-2034
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Attractiveness Analysis, by Distribution Channel
10. Global Prostate Health Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2020-2034
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness By Region
11. North America Prostate Health Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Disease Type, 2020-2034
11.2.1. Prostatitis
11.2.2. Benign Prostatic Hyperplasia (BPH)
11.2.3. Prostate Cancer
11.2.3.1. Adenocarcinoma
11.2.3.2. Transitional Cell Carcinoma
11.2.3.3. Squamous Cell Carcinoma
11.2.3.4. Small Cell Prostate Cancer
11.3. Market Value Forecast, by Treatment, 2020-2034
11.3.1. Chemotherapy
11.3.2. Hormone Therapy
11.3.3. Immunotherapy
11.4. Market Value Forecast, by Route of Administration, 2020-2034
11.4.1. Oral
11.4.2. Parenteral
11.5. Market Value Forecast, by Distribution Channel, 2020-2034
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. Market Value Forecast, by Country
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Disease Type
11.7.2. By Treatment
11.7.3. By Route of Administration
11.7.4. By Distribution Channel
11.7.5. By Country
12. Europe Prostate Health Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Disease Type, 2020-2034
12.2.1. Prostatitis
12.2.2. Benign Prostatic Hyperplasia (BPH)
12.2.3. Prostate Cancer
12.2.3.1. Adenocarcinoma
12.2.3.2. Transitional Cell Carcinoma
12.2.3.3. Squamous Cell Carcinoma
12.2.3.4. Small Cell Prostate Cancer
12.3. Market Value Forecast, by Treatment, 2020-2034
12.3.1. Chemotherapy
12.3.2. Hormone Therapy
12.3.3. Immunotherapy
12.4. Market Value Forecast, by Route of Administration, 2020-2034
12.4.1. Oral
12.4.2. Parenteral
12.5. Market Value Forecast, by Distribution Channel, 2020-2034
12.5.1. Hospital Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Online Pharmacies
12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
12.6.1. Germany
12.6.2. UK
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Disease Type
12.7.2. By Treatment
12.7.3. By Route of Administration
12.7.4. By Distribution Channel
12.7.5. By Country/Sub-region
13. Asia Pacific Prostate Health Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Disease Type, 2020-2034
13.2.1. Prostatitis
13.2.2. Benign prostatic hyperplasia (BPH)
13.2.3. Prostate Cancer
13.2.3.1. Adenocarcinoma
13.2.3.2. Transitional Cell Carcinoma
13.2.3.3. Squamous Cell Carcinoma
13.2.3.4. Small Cell Prostate Cancer
13.3. Market Value Forecast, by Treatment, 2020-2034
13.3.1. Chemotherapy
13.3.2. Hormone Therapy
13.3.3. Immunotherapy
13.4. Market Value Forecast, by Route of Administration, 2020-2034
13.4.1. Oral
13.4.2. Parenteral
13.5. Market Value Forecast, by Distribution Channel, 2020-2034
13.5.1. Hospital Pharmacies
13.5.2. Retail Pharmacies
13.5.3. Online Pharmacies
13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Disease Type
13.7.2. By Treatment
13.7.3. By Route of Administration
13.7.4. By Distribution Channel
13.7.5. By Country/Sub-region
14. Latin America Prostate Health Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Disease Type, 2020-2034
14.2.1. Prostatitis
14.2.2. Benign prostatic hyperplasia (BPH)
14.2.3. Prostate Cancer
14.2.3.1. Adenocarcinoma
14.2.3.2. Transitional Cell Carcinoma
14.2.3.3. Squamous Cell Carcinoma
14.2.3.4. Small Cell Prostate Cancer
14.3. Market Value Forecast, by Treatment, 2020-2034
14.3.1. Chemotherapy
14.3.2. Hormone Therapy
14.3.3. Immunotherapy
14.4. Market Value Forecast, by Route of Administration, 2020-2034
14.4.1. Oral
14.4.2. Parenteral
14.5. Market Value Forecast, by Distribution Channel, 2020-2034
14.5.1. Hospital Pharmacies
14.5.2. Retail Pharmacies
14.5.3. Online Pharmacies
14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Disease Type
14.7.2. By Treatment
14.7.3. By Route of Administration
14.7.4. By Distribution Channel
14.7.5. By Country/Sub-region
15. Middle East & Africa Prostate Health Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Disease Type, 2020-2034
15.2.1. Prostatitis
15.2.2. Benign prostatic hyperplasia (BPH)
15.2.3. Prostate Cancer
15.2.3.1. Adenocarcinoma
15.2.3.2. Transitional Cell Carcinoma
15.2.3.3. Squamous Cell Carcinoma
15.2.3.4. Small Cell Prostate Cancer
15.3. Market Value Forecast, by Treatment, 2020-2034
15.3.1. Chemotherapy
15.3.2. Hormone Therapy
15.3.3. Immunotherapy
15.4. Market Value Forecast, by Route of Administration, 2020-2034
15.4.1. Oral
15.4.2. Parenteral
15.5. Market Value Forecast, by Distribution Channel, 2020-2034
15.5.1. Hospital Pharmacies
15.5.2. Retail Pharmacies
15.5.3. Online Pharmacies
15.6. Market Value Forecast, by Country/Sub-region, 2020-2034
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Disease Type
15.7.2. By Treatment
15.7.3. By Route of Administration
15.7.4. By Distribution Channel
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of companies)
16.2. Market Share Analysis By Company (2023)
16.3. Company Profiles
16.3.1. Abbott Laboratories
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Amgen Inc.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Astellas Pharma Inc.
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. AstraZeneca PLC
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Bayer AG
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Bristol-Myers Squibb (BMS)
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Eli Lilly and Company
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Ferring Pharmaceuticals
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. GSK PLC.
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Johnson & Johnson
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
16.3.11. Merck and Co. Inc.
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Product Portfolio
16.3.11.3. Financial Overview
16.3.11.4. SWOT Analysis
16.3.11.5. Strategic Overview
16.3.12. Pfizer Inc.
16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.12.2. Product Portfolio
16.3.12.3. Financial Overview
16.3.12.4. SWOT Analysis
16.3.12.5. Strategic Overview
16.3.13. Siemens Healthineers AG
16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.13.2. Product Portfolio
16.3.13.3. Financial Overview
16.3.13.4. SWOT Analysis
16.3.13.5. Strategic Overview